These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 11681769)

  • 21. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
    Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
    Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacotherapy and psychotherapy for body dysmorphic disorder.
    Ipser JC; Sander C; Stein DJ
    Cochrane Database Syst Rev; 2009 Jan; 2009(1):CD005332. PubMed ID: 19160252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacotherapy in body dysmorphic disorder: relapse prevention and novel treatments.
    Dong N; Nezgovorova V; Hong K; Hollander E
    Expert Opin Pharmacother; 2019 Jul; 20(10):1211-1219. PubMed ID: 31038370
    [No Abstract]   [Full Text] [Related]  

  • 24. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762].
    Carey PD; Vythilingum B; Seedat S; Muller JE; van Ameringen M; Stein DJ
    BMC Psychiatry; 2005 Jan; 5():5. PubMed ID: 15667657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment-resistant anxiety disorders: A literature review of drug therapy strategies].
    Ammar G; Naja WJ; Pelissolo A
    Encephale; 2015 Jun; 41(3):260-5. PubMed ID: 25439852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
    Storch EA; Goddard AW; Grant JE; De Nadai AS; Goodman WK; Mutch PJ; Medlock C; Odlaug B; McDougle CJ; Murphy TK
    J Clin Psychiatry; 2013 Jun; 74(6):e527-32. PubMed ID: 23842022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study.
    Bogan AM; Koran LM; Chuong HW; Vapnik T; Bystritsky A
    J Clin Psychiatry; 2005 Jan; 66(1):73-9. PubMed ID: 15669891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Mohr N; Vythilingum B; Emsley RA; Stein DJ
    Int Clin Psychopharmacol; 2002 Jan; 17(1):37-40. PubMed ID: 11800505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus panel.
    Schatzberg AF; Haddad P; Kaplan EM; Lejoyeux M; Rosenbaum JF; Young AH; Zajecka J
    J Clin Psychiatry; 1997; 58 Suppl 7():5-10. PubMed ID: 9219487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
    Zheng H; Jia F; Han H; Wang S; Guo G; Quan D; Li G; Huang H
    Eur Neuropsychopharmacol; 2019 Mar; 29(3):397-404. PubMed ID: 30595354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacotherapy in paediatric obsessive-compulsive disorder: a naturalistic, retrospective study.
    Masi G; Millepiedi S; Perugi G; Pfanner C; Berloffa S; Pari C; Mucci M
    CNS Drugs; 2009; 23(3):241-52. PubMed ID: 19320532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Issues in the pharmacological treatment of obsessive-compulsive disorder.
    Math SB; Janardhan Reddy YC
    Int J Clin Pract; 2007 Jul; 61(7):1188-97. PubMed ID: 17511795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study.
    Kordon A; Wahl K; Koch N; Zurowski B; Anlauf M; Vielhaber K; Kahl KG; Broocks A; Voderholzer U; Hohagen F
    J Clin Psychopharmacol; 2008 Oct; 28(5):550-4. PubMed ID: 18794652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
    Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
    JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aripiprazole as an augmentation agent in treatment-resistant body dysmorphic disorder.
    Uzun O; Ozdemir B
    Clin Drug Investig; 2010; 30(10):707-10. PubMed ID: 20701402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review.
    Zajecka J; Tracy KA; Mitchell S
    J Clin Psychiatry; 1997 Jul; 58(7):291-7. PubMed ID: 9269249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial.
    Metin O; Yazici K; Tot S; Yazici AE
    Hum Psychopharmacol; 2003 Aug; 18(6):463-7. PubMed ID: 12923825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trichotillomania in youth: a retrospective case series.
    Mancini C; Van Ameringen M; Patterson B; Simpson W; Truong C
    Depress Anxiety; 2009; 26(7):661-5. PubMed ID: 19496078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
    Denys D; de Geus F; van Megen HJ; Westenberg HG
    J Clin Psychiatry; 2004 Aug; 65(8):1040-8. PubMed ID: 15323587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder.
    Masi G; Pfanner C; Millepiedi S; Berloffa S
    J Clin Psychopharmacol; 2010 Dec; 30(6):688-93. PubMed ID: 21105283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.